





UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/913,419	08/08/2001	Jamie Rossjohn	3991/OJ678	9005	
7278 D.A. D.D.V. (1)	7590 09/03/2003	•	EXAMI		
P. O. BOX 52	DARBY P.C. 257 , NY 10150-5257		MERTZ, PREMA MARIA		
7.2	,		ART UNIT	PAPER NUMBER	
		Ĭ	1646 DATE MAILED: 09/03/2003	12	

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

,

SERIAL NUMBER	FILING DATE	<u> </u>	FIRST NAMED APPLICANT			ATTORNEY DOCKET NO.	
		· · · · · · · · · · · · · · · · · · ·		-		EXAMINER	
					ART UNIT	PAPER NUMBER	
		• •		1	DATE MAILED:	12	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

1. There are specific amino acid residues provided in claims 5-7, 11 and 18. However, there are no SEQ ID NOS provided such that the specific amino acid residues correspond to amino acid residues present in SEQ ID NOS. Therefore, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should

be directed to Prema Mertz ose telephone number is (703) 308-4 reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Official papers filed by fax should be directed to (703) 305-3014 or (703 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 746-5300.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark Office on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Prema Mertz Ph.D. Primary Examiner Art Unit 1646 July 15, 2003

09/9/341	9
----------	---

Application No.:_

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	 This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: There are Grendick anyons and residues revited in claims 5-7,1 in the above of 10 NOs.
	plicant Must Provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

For Patentin software help, call (703) 308-6856